Trial Outcomes & Findings for Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age (NCT NCT00976820)

NCT ID: NCT00976820

Last Updated: 2017-12-12

Results Overview

A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal hemagglutination inhibition (HI) titer lower than (\<) 10 and a post-vaccination reciprocal HI titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 323 participants
• Primary outcome timeframe: At Day 21
• Results posted on: 2017-12-12

Participant Flow

Out of the 323 subjects originally enrolled in the study, 1 subject was not included in the Total Vaccinated Cohort.

Participant milestones

Measure	Arepanrix/F1 Group Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh \[for children under (\<) 12 months of age\]. The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F2 Group Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Overall Study STARTED	67	128	64	63
Overall Study COMPLETED	59	108	60	56
Overall Study NOT COMPLETED	8	20	4	7

Reasons for withdrawal

Measure	Arepanrix/F1 Group Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh \[for children under (\<) 12 months of age\]. The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F2 Group Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Overall Study Lost to Follow-up	5	16	2	3
Overall Study Poor Compliance. Numerous Visits Booked	1	0	1	0
Overall Study Withdrawal by Subject	2	4	1	4

Baseline Characteristics

Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

Baseline characteristics by cohort

Measure	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F2 Group n=128 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Total n=322 Participants Total of all reporting groups
Age, Continuous	53.6 Months STANDARD_DEVIATION 31.6 • n=5 Participants	47.4 Months STANDARD_DEVIATION 28.6 • n=7 Participants	50.3 Months STANDARD_DEVIATION 29.0 • n=5 Participants	54.4 Months STANDARD_DEVIATION 30.4 • n=4 Participants	50.6 Months STANDARD_DEVIATION 29.7 • n=21 Participants
Sex: Female, Male Female	27 Participants n=5 Participants	58 Participants n=7 Participants	33 Participants n=5 Participants	30 Participants n=4 Participants	148 Participants n=21 Participants
Sex: Female, Male Male	40 Participants n=5 Participants	70 Participants n=7 Participants	31 Participants n=5 Participants	33 Participants n=4 Participants	174 Participants n=21 Participants
Race/Ethnicity, Customized African heritage/African American	1 Participants n=5 Participants	7 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	10 Participants n=21 Participants
Race/Ethnicity, Customized American Indian or Alaskan native	1 Participants n=5 Participants	6 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	10 Participants n=21 Participants
Race/Ethnicity, Customized Asian - Central/South Asian heritage	14 Participants n=5 Participants	16 Participants n=7 Participants	16 Participants n=5 Participants	14 Participants n=4 Participants	60 Participants n=21 Participants
Race/Ethnicity, Customized Asian - East Asian heritage	2 Participants n=5 Participants	4 Participants n=7 Participants	0 Participants n=5 Participants	2 Participants n=4 Participants	8 Participants n=21 Participants
Race/Ethnicity, Customized Asian - South East Asian heritage	3 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	2 Participants n=4 Participants	8 Participants n=21 Participants
Race/Ethnicity, Customized White - Arabic/North African heritage	0 Participants n=5 Participants	3 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	4 Participants n=21 Participants
Race/Ethnicity, Customized White - Caucasian/European heritage	46 Participants n=5 Participants	86 Participants n=7 Participants	44 Participants n=5 Participants	38 Participants n=4 Participants	214 Participants n=21 Participants
Race/Ethnicity, Customized Not specified	0 Participants n=5 Participants	5 Participants n=7 Participants	0 Participants n=5 Participants	3 Participants n=4 Participants	8 Participants n=21 Participants

PRIMARY outcome

Timeframe: At Day 21

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal hemagglutination inhibition (HI) titer lower than (<) 10 and a post-vaccination reciprocal HI titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.

Outcome measures

Measure	Arepanrix/F2 Group n=55 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=58 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=60 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis	53 Participants	45 Participants	36 Participants	60 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 21

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer < 10 and a post-vaccination reciprocal titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.

Outcome measures

Measure	Arepanrix/F2 Group n=47 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=55 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=57 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=57 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis	45 Participants	41 Participants	34 Participants	54 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 21

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer < 10 and a post-vaccination reciprocal titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.

Outcome measures

Measure	Arepanrix/F2 Group n=101 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=54 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=57 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=59 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	98 Participants	41 Participants	34 Participants	56 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 42

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer < 10 and a post-vaccination reciprocal titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.

Outcome measures

Measure	Arepanrix/F2 Group n=40 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=43 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis	39 Participants	46 Participants	38 Participants	43 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 42

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer < 10 and a post-vaccination reciprocal titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.

Outcome measures

Measure	Arepanrix/F2 Group n=84 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	83 Participants	46 Participants	38 Participants	44 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 0

Population: The analysis was performed on the Total Vaccinated Cohort at Day 21, which included all subjects who received at least 1 study vaccination.

A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.

Outcome measures

Measure	Arepanrix/F2 Group n=59 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=61 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=62 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=66 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis	3 Participants	12 Participants	15 Participants	13 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 21

Population: The analysis was performed on the Total Vaccinated Cohort at Day 21, which included all subjects who received at least 1 study vaccination.

A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.

Outcome measures

Measure	Arepanrix/F2 Group n=56 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=59 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=60 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis	55 Participants	46 Participants	39 Participants	62 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 0

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.

Outcome measures

Measure	Arepanrix/F2 Group n=49 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=55 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=58 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=57 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis	2 Participants	12 Participants	14 Participants	12 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 21

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.

Outcome measures

Measure	Arepanrix/F2 Group n=49 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=55 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=57 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=57 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis	48 Participants	42 Participants	37 Participants	56 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 0

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.

Outcome measures

Measure	Arepanrix/F2 Group n=102 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=54 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=58 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=59 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	24 Participants	12 Participants	14 Participants	12 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 21

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.

Outcome measures

Measure	Arepanrix/F2 Group n=103 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=54 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=57 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=59 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	102 Participants	42 Participants	37 Participants	58 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 0

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.

Outcome measures

Measure	Arepanrix/F2 Group n=40 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=43 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - First Analysis	1 Participants	9 Participants	9 Participants	8 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 42

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.

Outcome measures

Measure	Arepanrix/F2 Group n=42 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=43 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis	42 Participants	46 Participants	41 Participants	43 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 0

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.

Outcome measures

Measure	Arepanrix/F2 Group n=84 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - Second Analysis	20 Participants	9 Participants	9 Participants	8 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 42

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.

Outcome measures

Measure	Arepanrix/F2 Group n=87 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	87 Participants	46 Participants	41 Participants	44 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 21

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.

Outcome measures

Measure	Arepanrix/F2 Group n=55 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=58 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=60 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis	39.2 Fold change Interval 29.2 to 52.5	14.4 Fold change Interval 10.2 to 20.4	7.8 Fold change Interval 5.6 to 11.0	38.6 Fold change Interval 28.8 to 51.8	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 21

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.

Outcome measures

Measure	Arepanrix/F2 Group n=47 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=55 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=57 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=57 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis	40.8 Fold change Interval 29.7 to 56.2	13.2 Fold change Interval 9.2 to 18.8	7.6 Fold change Interval 5.4 to 10.6	35.9 Fold change Interval 26.4 to 49.0	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 21

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.

Outcome measures

Measure	Arepanrix/F2 Group n=101 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=54 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=57 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=59 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	33.6 Fold change Interval 27.3 to 41.3	13.8 Fold change Interval 9.7 to 19.6	7.6 Fold change Interval 5.4 to 10.6	36.2 Fold change Interval 26.8 to 48.9	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 42

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.

Outcome measures

Measure	Arepanrix/F2 Group n=40 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=43 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis	217.2 Fold change Interval 163.9 to 287.9	44.2 Fold change Interval 30.6 to 63.9	24.1 Fold change Interval 15.9 to 36.5	155.3 Fold change Interval 105.7 to 228.2	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At Day 42

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.

Outcome measures

Measure	Arepanrix/F2 Group n=84 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	151.6 Fold change Interval 114.0 to 201.6	44.2 Fold change Interval 30.6 to 63.9	24.1 Fold change Interval 15.9 to 36.5	157.1 Fold change Interval 107.8 to 228.9	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 21

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.

Outcome measures

Measure	Arepanrix/F2 Group n=59 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=61 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=62 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=66 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seropositive Subjects for HI Antibodies - Preliminary Analysis Flu A/CAL/7/09, PRE	4 Participants	13 Participants	15 Participants	17 Participants	—	—	—	—	—	—	—	—	—
Number of Seropositive Subjects for HI Antibodies - Preliminary Analysis Flu A/CAL/7/09, D21	56 Participants	57 Participants	56 Participants	63 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 21

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.

Outcome measures

Measure	Arepanrix/F2 Group n=49 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=55 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=58 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=57 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seropositive Subjects for HI Antibodies - First Analysis Flu A/CAL/7/09, PRE	3 Participants	13 Participants	14 Participants	15 Participants	—	—	—	—	—	—	—	—	—
Number of Seropositive Subjects for HI Antibodies - First Analysis Flu A/CAL/7/09, D21	49 Participants	53 Participants	54 Participants	57 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 21

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.

Outcome measures

Measure	Arepanrix/F2 Group n=103 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=54 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=58 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=59 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seropositive Subjects for HI Antibodies - Second Analysis Flu A/CAL/7/09, PRE	27 Participants	13 Participants	14 Participants	15 Participants	—	—	—	—	—	—	—	—	—
Number of Seropositive Subjects for HI Antibodies - Second Analysis Flu A/CAL/7/09, D21	103 Participants	53 Participants	54 Participants	59 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 42

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.

Outcome measures

Measure	Arepanrix/F2 Group n=42 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=43 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seropositive Subjects for HI Antibodies - First Analysis Flu A/CAL/7/09, PRE	2 Participants	10 Participants	9 Participants	10 Participants	—	—	—	—	—	—	—	—	—
Number of Seropositive Subjects for HI Antibodies - First Analysis Flu A/CAL/7/09, D42	42 Participants	46 Participants	44 Participants	43 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 42

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.

Outcome measures

Measure	Arepanrix/F2 Group n=87 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seropositive Subjects for HI Antibodies - Second Analysis Flu A/CAL/7/09, PRE	23 Participants	10 Participants	9 Participants	10 Participants	—	—	—	—	—	—	—	—	—
Number of Seropositive Subjects for HI Antibodies - Second Analysis Flu A/CAL/7/09, D42	87 Participants	46 Participants	44 Participants	44 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 182

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 182, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.

Outcome measures

Measure	Arepanrix/F2 Group n=84 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=47 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=52 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=54 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seropositive Subjects for HI Antibodies Flu A/CAL/7/09, PRE	18 Participants	13 Participants	12 Participants	13 Participants	—	—	—	—	—	—	—	—	—
Number of Seropositive Subjects for HI Antibodies Flu A/CAL/7/09, D182	84 Participants	45 Participants	50 Participants	54 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 21

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Titers are presented as geometric mean titers (GMTs) and measured in titers.

Outcome measures

Measure	Arepanrix/F2 Group n=59 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=61 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=62 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=66 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis Flu A/CAL/7/09, PRE	6.2 Titers Interval 4.9 to 7.7	9.8 Titers Interval 6.9 to 13.9	10.9 Titers Interval 7.6 to 15.7	10.3 Titers Interval 7.4 to 14.5	—	—	—	—	—	—	—	—	—
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis Flu A/CAL/7/09, D21	253.0 Titers Interval 185.8 to 344.4	141.4 Titers Interval 90.8 to 220.1	82.7 Titers Interval 52.9 to 129.5	387.9 Titers Interval 286.7 to 524.8	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 21

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

Titers are presented as geometric mean titers (GMTs) and measured in titers.

Outcome measures

Measure	Arepanrix/F2 Group n=49 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=55 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=58 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=57 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis Flu A/CAL/7/09, PRE	6.1 Titers Interval 4.7 to 7.8	10.5 Titers Interval 7.2 to 15.5	10.9 Titers Interval 7.5 to 15.8	10.8 Titers Interval 7.4 to 15.6	—	—	—	—	—	—	—	—	—
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis Flu A/CAL/7/09, D21	270.1 Titers Interval 194.2 to 375.5	138.4 Titers Interval 86.3 to 222.0	83.4 Titers Interval 52.9 to 131.4	386.4 Titers Interval 280.3 to 532.6	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 21

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

Titers are presented as geometric mean titers (GMTs) and measured in titers.

Outcome measures

Measure	Arepanrix/F2 Group n=103 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=54 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=58 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=59 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis Flu A/CAL/7/09, PRE	10.8 Titers Interval 8.2 to 14.3	10.7 Titers Interval 7.2 to 15.8	10.9 Titers Interval 7.5 to 15.8	10.5 Titers Interval 7.3 to 15.1	—	—	—	—	—	—	—	—	—
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis Flu A/CAL/7/09, D21	377.3 Titers Interval 299.6 to 475.3	147.2 Titers Interval 92.4 to 234.3	83.4 Titers Interval 52.9 to 131.4	379.4 Titers Interval 277.9 to 518.0	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 42

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

Titers are presented as geometric mean titers (GMTs) and measured in titers.

Outcome measures

Measure	Arepanrix/F2 Group n=42 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=43 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis Flu A/CAL/7/09, PRE	5.7 Titers Interval 4.6 to 7.1	9.3 Titers Interval 6.4 to 13.6	9.5 Titers Interval 6.4 to 14.0	9.3 Titers Interval 6.4 to 13.5	—	—	—	—	—	—	—	—	—
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis Flu A/CAL/7/09, D42	1238.5 Titers Interval 1050.2 to 1460.5	413.5 Titers Interval 296.6 to 576.4	228.0 Titers Interval 156.9 to 331.3	1444.4 Titers Interval 1146.0 to 1820.6	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 42

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

Titers are presented as geometric mean titers (GMTs) and measured in titers.

Outcome measures

Measure	Arepanrix/F2 Group n=87 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis Flu A/CAL/7/09, PRE	11.1 Titers Interval 8.2 to 15.1	9.3 Titers Interval 6.4 to 13.6	9.5 Titers Interval 6.4 to 14.0	9.2 Titers Interval 6.3 to 13.2	—	—	—	—	—	—	—	—	—
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis Flu A/CAL/7/09, D42	1671.6 Titers Interval 1471.8 to 1898.4	413.5 Titers Interval 296.6 to 576.4	228.0 Titers Interval 156.9 to 331.3	1440.5 Titers Interval 1149.0 to 1805.8	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 182

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 182, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

Titers are presented as geometric mean titers (GMTs) and measured in titers.

Outcome measures

Measure	Arepanrix/F2 Group n=84 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=47 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=52 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=54 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain Flu A/CAL/7/09, PRE	10.0 Titers Interval 7.3 to 13.6	11.9 Titers Interval 7.7 to 18.6	10.6 Titers Interval 7.2 to 15.7	9.6 Titers Interval 6.8 to 13.5	—	—	—	—	—	—	—	—	—
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain Flu A/CAL/7/09, D182	267.9 Titers Interval 219.5 to 327.0	122.7 Titers Interval 86.4 to 174.3	82.8 Titers Interval 59.5 to 115.2	296.2 Titers Interval 230.5 to 380.8	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 182

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 182, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal hemagglutination inhibition (HI) titer lower than (<) 10 and a post-vaccination reciprocal titer higher than or equal to (≥) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.

Outcome measures

Measure	Arepanrix/F2 Group n=82 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=47 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=52 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=54 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain	78 Participants	35 Participants	34 Participants	50 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 182

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 182, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (≥) 40 against the tested virus.

Outcome measures

Measure	Arepanrix/F2 Group n=84 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=47 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=52 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=54 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain Flu A/CAL/7/09, PRE	16 Participants	12 Participants	12 Participants	10 Participants	—	—	—	—	—	—	—	—	—
Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain Flu A/CAL/7/09, D182	84 Participants	43 Participants	43 Participants	53 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 182

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 182, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.

Outcome measures

Measure	Arepanrix/F2 Group n=82 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=47 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=52 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=54 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain	26.6 Fold change Interval 20.6 to 34.3	10.3 Fold change Interval 7.1 to 14.8	7.8 Fold change Interval 5.5 to 10.9	31.0 Fold change Interval 22.7 to 42.4	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 21

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:8. The vaccine strain assessed was Flu A/Neth/602/09 H1N1.

Outcome measures

Measure	Arepanrix/F2 Group n=84 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=55 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=52 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain Flu A/Neth/602/09, PRE	30 Participants	17 Participants	20 Participants	25 Participants	—	—	—	—	—	—	—	—	—
Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain Flu A/Neth/602/09, D21	82 Participants	39 Participants	35 Participants	51 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 21

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

Titers are presented as geometric mean titers (GMTs) and measured in titers.

Outcome measures

Measure	Arepanrix/F2 Group n=84 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=55 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=52 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain Flu A/Neth/602/09, PRE	13.8 Titers Interval 9.0 to 20.9	15.0 Titers Interval 8.2 to 27.2	15.3 Titers Interval 8.8 to 26.6	19.3 Titers Interval 11.1 to 33.5	—	—	—	—	—	—	—	—	—
Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain Flu A/Neth/602/09, D21	296.1 Titers Interval 181.7 to 482.7	231.1 Titers Interval 111.9 to 477.3	138.3 Titers Interval 63.2 to 302.7	427.6 Titers Interval 244.5 to 748.0	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 42

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

A seropositive subject was defined as a subject with antibody titers greater than or equal to (≥) 1:8. The vaccine strain assessed was Flu A/Neth/602/09 H1N1.

Outcome measures

Measure	Arepanrix/F2 Group n=68 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=36 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=42 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=40 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain Flu A/Neth/602/09, PRE	26 Participants	13 Participants	13 Participants	18 Participants	—	—	—	—	—	—	—	—	—
Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain Flu A/Neth/602/09, D42	63 Participants	35 Participants	33 Participants	34 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 42

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

Titers are presented as geometric mean titers (GMTs) and measured in titers.

Outcome measures

Measure	Arepanrix/F2 Group n=68 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=36 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=42 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=40 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain Flu A/Neth/602/09, PRE	15.0 Titers Interval 9.3 to 24.1	12.0 Titers Interval 6.7 to 21.4	13.6 Titers Interval 7.3 to 25.5	16.7 Titers Interval 9.1 to 30.8	—	—	—	—	—	—	—	—	—
Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain Flu A/Neth/602/09, D42	1786.9 Titers Interval 1258.6 to 2537.0	428.4 Titers Interval 208.7 to 879.6	146.1 Titers Interval 74.3 to 287.5	1389.3 Titers Interval 835.5 to 2310.4	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 21

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 21, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

Vaccine responses are defined as the incidence rate of vaccinated subjects with at least a 4-fold increase in post vaccination reciprocal titer relative to that prior to first vaccination. The vaccine strain assessed was Flu A/Neth/602/09 H1N1.

Outcome measures

Measure	Arepanrix/F2 Group n=70 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=37 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=43 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=45 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations	57 Participants	27 Participants	24 Participants	41 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE) and at Day 42

Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects who met all eligibility criteria, who complied with the protocol requirements and for whom immunogenicity measures were available.

Vaccine response was defined as at least a 4-fold increase in post vaccination reciprocal titer relative to that prior to first vaccination. The vaccine strain assessed was Flu A/Neth/602/09.

Outcome measures

Measure	Arepanrix/F2 Group n=54 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=30 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=34 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=32 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations	54 Participants	26 Participants	23 Participants	31 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: During the 7-day (Days 0-6) post-vaccination period

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Outcome measures

Measure	Arepanrix/F2 Group n=18 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=48 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=12 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=47 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group n=45 Participants Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group n=17 Participants Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group n=44 Participants Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group n=18 Participants Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis Grade 3 Pain	1 Participants	0 Participants	0 Participants	4 Participants	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis Grade 3 Swelling	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis Any Pain	14 Participants	26 Participants	9 Participants	27 Participants	18 Participants	12 Participants	15 Participants	10 Participants	—	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis Any Redness	4 Participants	4 Participants	2 Participants	5 Participants	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis Grade 3 Redness	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis Any Swelling	2 Participants	1 Participants	1 Participants	1 Participants	1 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—

SECONDARY outcome

Timeframe: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Outcome measures

Measure	Arepanrix/F2 Group n=18 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=1 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=49 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=47 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group n=12 Participants Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group n=46 Participants Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group n=17 Participants Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group n=44 Participants Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group n=18 Participants Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Grade 3 Pain, Dose 1	1 Participants	0 Participants	0 Participants	4 Participants	0 Participants	1 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Grade 3 Swelling, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Any Swelling, Dose 2	1 Participants	0 Participants	2 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Any Pain, Dose 1	14 Participants	1 Participants	26 Participants	27 Participants	9 Participants	19 Participants	12 Participants	15 Participants	10 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Any Redness, Dose 1	4 Participants	0 Participants	4 Participants	5 Participants	2 Participants	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Grade 3 Redness, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Any Swelling, Dose 1	2 Participants	0 Participants	1 Participants	1 Participants	1 Participants	1 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Any Pain, Dose 2	13 Participants	0 Participants	25 Participants	22 Participants	7 Participants	11 Participants	8 Participants	9 Participants	7 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Grade 3 Pain, Dose 2	0 Participants	0 Participants	1 Participants	4 Participants	2 Participants	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Any Redness, Dose 2	1 Participants	0 Participants	3 Participants	5 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Grade 3 Redness, Dose 2	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Grade 3 Swelling, Dose 2	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Any Pain, Across doses	15 Participants	1 Participants	33 Participants	35 Participants	9 Participants	22 Participants	12 Participants	18 Participants	12 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Grade 3 Pain, Across doses	1 Participants	0 Participants	1 Participants	7 Participants	2 Participants	1 Participants	1 Participants	0 Participants	1 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Any Redness, Across doses	4 Participants	0 Participants	6 Participants	7 Participants	2 Participants	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Grade 3 Redness, Across doses	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Any Swelling, Across doses	2 Participants	0 Participants	3 Participants	2 Participants	1 Participants	1 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis Grade 3 Swelling, Across doses	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—

SECONDARY outcome

Timeframe: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Outcome measures

Measure	Arepanrix/F2 Group n=25 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=18 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=1 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=22 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group n=46 Participants Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group n=53 Participants Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group n=26 Participants Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group n=24 Participants Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group n=22 Participants Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group n=17 Participants Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group n=23 Participants Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group n=21 Participants Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group n=18 Participants Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Grade 3 Pain, Dose 1	2 Participants	1 Participants	0 Participants	2 Participants	1 Participants	3 Participants	2 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Any Redness, Dose 1	3 Participants	4 Participants	0 Participants	2 Participants	4 Participants	4 Participants	2 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Grade 3 Swelling, Dose 2	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Any Redness, Across Doses	4 Participants	4 Participants	0 Participants	3 Participants	5 Participants	5 Participants	2 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Any Swelling, Across Doses	2 Participants	2 Participants	0 Participants	0 Participants	4 Participants	4 Participants	3 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Grade 3 Redness, Across Doses	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Grade 3 Swelling, Across Doses	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Any Pain, Dose 1	15 Participants	14 Participants	1 Participants	12 Participants	20 Participants	34 Participants	22 Participants	10 Participants	9 Participants	12 Participants	8 Participants	7 Participants	10 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Grade 3 Redness, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Any Swelling, Dose 1	1 Participants	2 Participants	0 Participants	0 Participants	3 Participants	2 Participants	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Grade 3 Swelling, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Any Pain, Dose 2	10 Participants	13 Participants	0 Participants	12 Participants	18 Participants	35 Participants	19 Participants	5 Participants	6 Participants	8 Participants	4 Participants	5 Participants	7 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Grade 3 Pain, Dose 2	1 Participants	0 Participants	0 Participants	3 Participants	3 Participants	2 Participants	3 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Any Redness, Dose 2	3 Participants	1 Participants	0 Participants	2 Participants	1 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Grade 3 Redness, Dose 2	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Any Swelling, Dose 2	1 Participants	1 Participants	0 Participants	0 Participants	1 Participants	3 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Any Pain, Across Doses	19 Participants	15 Participants	1 Participants	16 Participants	25 Participants	44 Participants	22 Participants	11 Participants	11 Participants	12 Participants	9 Participants	9 Participants	12 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis Grade 3 Pain, Across Doses	3 Participants	1 Participants	0 Participants	4 Participants	3 Participants	5 Participants	5 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants

SECONDARY outcome

Timeframe: During the 7-day (Days 0-6) post-vaccination period

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 loss of appetite= not eating at all. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=48 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=45 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=47 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Grade 3 Drowsiness	1 Participants	0 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Any Temperature (Axillary)	6 Participants	2 Participants	1 Participants	8 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Grade 3 Temperature (Axillary)	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Any Drowsiness	11 Participants	8 Participants	9 Participants	11 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Related Drowsiness	8 Participants	5 Participants	7 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Any Irritability	18 Participants	14 Participants	8 Participants	22 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Grade 3 Irritability	3 Participants	0 Participants	0 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Related Irritability	15 Participants	12 Participants	8 Participants	19 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Any Loss of appetite	17 Participants	6 Participants	9 Participants	16 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Grade 3 Loss of appetite	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Related Loss of appetite	12 Participants	3 Participants	8 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Related Temperature (Axillary)	3 Participants	1 Participants	1 Participants	6 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: During the 7-day (Days 0-6) post-vaccination period

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, shivering, sweating, temperature [defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=12 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=17 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=18 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=18 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Related Gastro-intestinal symptoms	1 Participants	3 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Any Joint pain at other location	0 Participants	2 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Grade 3 Joint pain at other location	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Any Muscle aches	2 Participants	3 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Grade 3 Muscle aches	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Grade 3 Shivering	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Any Sweating	1 Participants	2 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Grade 3 Sweating	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Related Sweating	0 Participants	2 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Any Temperature (Axillary)	2 Participants	1 Participants	0 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Related Temperature (Axillary)	2 Participants	1 Participants	0 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Any Fatigue	4 Participants	4 Participants	4 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Grade 3 Fatigue	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Related Fatigue	3 Participants	4 Participants	3 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Any Gastro-intestinal symptoms	2 Participants	3 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Grade 3 Gastro-intestinal symptoms	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Any Headache	4 Participants	2 Participants	2 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Grade 3 Headache	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Related Headache	2 Participants	1 Participants	2 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Related Joint pain at other location	0 Participants	2 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Related Muscle aches	2 Participants	3 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Any Shivering	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Related Shivering	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis Grade 3 Temperature (Axillary)	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=49 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=44 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=47 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Loss of appetite, Dose 1	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Loss of appetite, Dose 1	12 Participants	3 Participants	8 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Temperature (Axillary), Dose 1	6 Participants	2 Participants	1 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Temperature (Axillary), Dose 1	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Drowsiness, Dose 1	11 Participants	8 Participants	9 Participants	11 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Drowsiness, Dose 1	1 Participants	0 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Drowsiness, Dose 1	8 Participants	5 Participants	7 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Irritability, Dose 1	18 Participants	15 Participants	8 Participants	22 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Irritability, Dose 1	3 Participants	1 Participants	0 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Drowsiness, Dose 2	6 Participants	7 Participants	7 Participants	13 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Drowsiness, Dose 2	2 Participants	5 Participants	7 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Irritability, Dose 2	1 Participants	2 Participants	2 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Irritability, Dose 2	11 Participants	12 Participants	11 Participants	18 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Loss of appetite, Dose 2	2 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Loss of appetite, Dose 2	8 Participants	5 Participants	5 Participants	15 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Temperature (Axillary), Dose 2	7 Participants	3 Participants	3 Participants	13 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Temperature (Axillary), Dose 2	0 Participants	0 Participants	0 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Temperature (Axillary), Dose 2	6 Participants	2 Participants	0 Participants	11 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Drowsiness, Across doses	15 Participants	13 Participants	14 Participants	17 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Drowsiness, Across doses	1 Participants	0 Participants	0 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Drowsiness, Across doses	9 Participants	9 Participants	12 Participants	10 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Irritability, Across doses	22 Participants	21 Participants	17 Participants	28 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Irritability, Across doses	4 Participants	3 Participants	2 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Irritability, Across doses	20 Participants	17 Participants	17 Participants	25 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Loss of appetite, Across doses	23 Participants	11 Participants	11 Participants	25 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Loss of appetite, Across doses	3 Participants	0 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Loss of appetite, Across doses	17 Participants	7 Participants	10 Participants	17 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Temperature (Axillary), Across doses	11 Participants	4 Participants	4 Participants	19 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Temperature (Axillary), Across doses	0 Participants	0 Participants	0 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Temperature (Axillary), Across doses	8 Participants	2 Participants	1 Participants	16 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Irritability, Dose 1	15 Participants	12 Participants	8 Participants	19 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Loss of appetite, Dose 1	17 Participants	6 Participants	9 Participants	16 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Temperature (Axillary), Dose 1	3 Participants	1 Participants	1 Participants	8 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Drowsiness, Dose 2	0 Participants	0 Participants	0 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Irritability, Dose 2	12 Participants	13 Participants	11 Participants	19 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Loss of appetite, Dose 2	10 Participants	7 Participants	5 Participants	18 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, and shivering, sweating, temperature [defined as axillary temperature equal to or above (≥) 38 degrees Celsius (° C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=12 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=17 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=18 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=18 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Fatigue, Dose 1	4 Participants	4 Participants	4 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Fatigue, Dose 1	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Fatigue, Dose 1	3 Participants	4 Participants	3 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Gastrointestinal symptoms, Dose 1	2 Participants	3 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Gastrointestinal symptoms, Dose 1	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Gastrointestinal symptoms, Dose 1	1 Participants	3 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Headache, Dose 1	4 Participants	2 Participants	2 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Headache, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Headache, Dose 1	2 Participants	1 Participants	2 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Joint pain at other location, Dose 1	0 Participants	2 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Joint pain at other location, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Joint pain at other location, Dose 1	0 Participants	2 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Muscle aches, Dose 1	2 Participants	3 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Muscle aches, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Muscle aches, Dose 1	2 Participants	3 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Shivering, Dose 1	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Shivering, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Shivering, Dose 1	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Sweating, Dose 1	1 Participants	2 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Sweating, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Sweating, Dose 1	0 Participants	2 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Temperature (Axillary), Dose 1	2 Participants	1 Participants	0 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Temperature (Axillary), Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Temperature (Axillary), Dose 1	2 Participants	1 Participants	0 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Fatigue, Dose 2	3 Participants	3 Participants	4 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Fatigue, Dose 2	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Fatigue, Dose 2	2 Participants	3 Participants	3 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Gastrointestinal symptoms, Dose 2	2 Participants	1 Participants	5 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Gastrointestinal symptoms, Dose 2	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Gastrointestinal symptoms, Dose 2	2 Participants	1 Participants	4 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Headache, Dose 2	3 Participants	2 Participants	4 Participants	8 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Headache, Dose 2	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Headache, Dose 2	3 Participants	2 Participants	3 Participants	8 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Joint pain at other location, Dose 2	4 Participants	0 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Joint pain at other location, Dose 2	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Joint pain at other location, Dose 2	4 Participants	0 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Muscle aches, Dose 2	2 Participants	1 Participants	2 Participants	7 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Muscle aches, Dose 2	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Shivering, Dose 2	2 Participants	2 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Shivering, Dose 2	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Shivering, Dose 2	2 Participants	2 Participants	0 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Sweating, Dose 2	1 Participants	0 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Sweating, Dose 2	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Sweating, Dose 2	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Temperature (Axillary), Dose 2	2 Participants	0 Participants	2 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Temperature (Axillary), Dose 2	0 Participants	0 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Temperature (Axillary), Dose 2	2 Participants	0 Participants	1 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Fatigue, Across doses	5 Participants	4 Participants	8 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Fatigue, Across doses	1 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Fatigue, Across doses	4 Participants	4 Participants	6 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Gastrointestinal symptoms, Across doses	3 Participants	3 Participants	7 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Gastrointestinal symptoms, Across doses	0 Participants	1 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Gastrointestinal symptoms, Across doses	3 Participants	3 Participants	4 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Headache, Across doses	5 Participants	4 Participants	5 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Headache, Across doses	4 Participants	3 Participants	4 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Joint pain at other location, Across doses	4 Participants	2 Participants	2 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Joint pain at other location, Across doses	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Joint pain at other location, Across doses	4 Participants	2 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Muscle aches, Across doses	3 Participants	3 Participants	3 Participants	8 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Muscle aches, Across doses	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Shivering, Across doses	2 Participants	2 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Shivering, Across doses	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Shivering, Across doses	2 Participants	2 Participants	0 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Sweating, Across doses	1 Participants	2 Participants	3 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Sweating, Across doses	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Sweating, Across doses	1 Participants	2 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Any Temperature (Axillary), Across doses	4 Participants	1 Participants	2 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Temperature (Axillary), Across doses	0 Participants	0 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Temperature (Axillary), Across doses	4 Participants	1 Participants	1 Participants	7 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Muscle aches, Dose 2	2 Participants	1 Participants	1 Participants	7 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Grade 3 Headache, Across doses	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis Related Muscle aches, Across doses	3 Participants	3 Participants	2 Participants	8 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=25 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=46 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=53 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=22 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group n=24 Participants Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group n=22 Participants Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group n=23 Participants Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group n=21 Participants Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Any Drowsiness, Dose 1	5 Participants	20 Participants	13 Participants	6 Participants	4 Participants	4 Participants	6 Participants	3 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Grade 3 Drowsiness, Dose 1	1 Participants	2 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Related Drowsiness, Dose 1	2 Participants	13 Participants	4 Participants	3 Participants	3 Participants	2 Participants	5 Participants	2 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Any Irritability, Dose 1	8 Participants	22 Participants	14 Participants	14 Participants	9 Participants	6 Participants	8 Participants	0 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Grade 3 Irritability, Dose 1	2 Participants	6 Participants	0 Participants	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Related Irritability, Dose 1	6 Participants	15 Participants	8 Participants	13 Participants	8 Participants	4 Participants	8 Participants	0 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Any Loss of appetite, Dose 1	7 Participants	19 Participants	12 Participants	9 Participants	2 Participants	4 Participants	8 Participants	1 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Related Loss of appetite, Dose 1	3 Participants	12 Participants	5 Participants	6 Participants	1 Participants	2 Participants	7 Participants	1 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Any Temperature (Axillary), Dose 1	4 Participants	6 Participants	9 Participants	5 Participants	0 Participants	2 Participants	0 Participants	1 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Grade 3 Temperature (Axillary), Dose 1	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Related Temperature (Axillary), Dose 1	4 Participants	1 Participants	2 Participants	4 Participants	0 Participants	1 Participants	0 Participants	1 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Any Drowsiness, Dose 2	5 Participants	9 Participants	9 Participants	8 Participants	5 Participants	2 Participants	5 Participants	2 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Grade 3 Drowsiness, Dose 2	2 Participants	0 Participants	0 Participants	3 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Related Drowsiness, Dose 2	2 Participants	5 Participants	5 Participants	7 Participants	4 Participants	1 Participants	5 Participants	2 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Any Irritability, Dose 2	6 Participants	23 Participants	10 Participants	13 Participants	10 Participants	3 Participants	6 Participants	5 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Grade 3 Irritability, Dose 2	1 Participants	1 Participants	0 Participants	2 Participants	1 Participants	1 Participants	1 Participants	1 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Related Irritability, Dose 2	5 Participants	19 Participants	8 Participants	13 Participants	9 Participants	3 Participants	6 Participants	5 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Any Loss of appetite, Dose 2	7 Participants	13 Participants	10 Participants	11 Participants	7 Participants	0 Participants	4 Participants	1 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Grade 3 Loss of appetite, Dose 2	1 Participants	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Related Loss of appetite, Dose 2	4 Participants	10 Participants	7 Participants	11 Participants	5 Participants	0 Participants	4 Participants	1 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Any Temperature (Axillary), Dose 2	3 Participants	6 Participants	8 Participants	10 Participants	2 Participants	1 Participants	1 Participants	2 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Grade 3 Temperature (Axillary), Dose 2	1 Participants	1 Participants	0 Participants	4 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Related Temperature (Axillary), Dose 2	2 Participants	5 Participants	5 Participants	9 Participants	1 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Any Drowsiness, Across doses	7 Participants	23 Participants	19 Participants	10 Participants	7 Participants	6 Participants	9 Participants	5 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Grade 3 Drowsiness, Across doses	2 Participants	2 Participants	0 Participants	4 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Related Drowsiness, Across doses	3 Participants	16 Participants	7 Participants	7 Participants	6 Participants	3 Participants	8 Participants	4 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Any Irritability, Across doses	9 Participants	30 Participants	20 Participants	19 Participants	14 Participants	7 Participants	12 Participants	5 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Grade 3 Irritability, Across doses	3 Participants	7 Participants	0 Participants	3 Participants	2 Participants	1 Participants	1 Participants	1 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Related Irritability, Across doses	7 Participants	23 Participants	14 Participants	18 Participants	12 Participants	5 Participants	12 Participants	5 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Any Loss of appetite, Across doses	10 Participants	26 Participants	19 Participants	15 Participants	7 Participants	4 Participants	9 Participants	2 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Grade 3 Loss of appetite, Across doses	1 Participants	3 Participants	2 Participants	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Related Loss of appetite, Across doses	5 Participants	19 Participants	10 Participants	12 Participants	5 Participants	2 Participants	8 Participants	2 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Any Temperature (Axillary), Across doses	6 Participants	10 Participants	14 Participants	13 Participants	2 Participants	2 Participants	1 Participants	3 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Grade 3 Temperature (Axillary), Across doses	2 Participants	1 Participants	0 Participants	4 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Related Temperature (Axillary), Across doses	5 Participants	6 Participants	6 Participants	11 Participants	1 Participants	1 Participants	0 Participants	1 Participants	—	—	—	—	—
Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis Grade 3 Loss of appetite, Dose 1	0 Participants	2 Participants	1 Participants	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—

SECONDARY outcome

Timeframe: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, shivering, sweating and temperature [defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=26 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=17 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=18 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=18 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Muscle aches, Dose 1	5 Participants	3 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Shivering, Dose 1	2 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Shivering, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Fatigue, Dose 1	8 Participants	4 Participants	4 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Fatigue, Dose 1	4 Participants	4 Participants	3 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Gastrointestinal symptoms, Dose 1	4 Participants	3 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Gastrointestinal symptoms, Dose 1	1 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Gastrointestinal symptoms, Dose 1	1 Participants	3 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Headache, Dose 1	9 Participants	2 Participants	2 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Headache, Dose 1	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Headache, Dose 1	3 Participants	1 Participants	2 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Joint pain at other location, Dose 1	5 Participants	2 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Joint pain at other location, Dose 1	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Joint pain at other location, Dose 1	1 Participants	2 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Muscle aches, Dose 1	7 Participants	3 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Muscle aches, Dose 1	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Shivering, Dose 1	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Sweating, Dose 1	2 Participants	2 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Sweating, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Sweating, Dose 1	0 Participants	2 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Temperature (Axillary), Dose 1	6 Participants	1 Participants	0 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Temperature (Axillary), Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Temperature (Axillary), Dose 1	2 Participants	1 Participants	0 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Fatigue, Dose 2	7 Participants	3 Participants	4 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Fatigue, Dose 2	2 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Fatigue, Dose 2	3 Participants	3 Participants	3 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Gastrointestinal symptoms, Dose 2	6 Participants	1 Participants	5 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Gastrointestinal symptoms, Dose 2	1 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Muscle aches, Dose 2	8 Participants	1 Participants	2 Participants	7 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Temperature (Axillary), Dose 2	6 Participants	0 Participants	2 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Temperature (Axillary), Dose 2	2 Participants	0 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Temperature (Axillary), Dose 2	4 Participants	0 Participants	1 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Fatigue, Across doses	2 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Gastrointestinal symptoms, Across doses	8 Participants	3 Participants	7 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Gastrointestinal symptoms, Across doses	1 Participants	1 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Headache, Across doses	1 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Joint pain at other location, Across doses	6 Participants	2 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Muscle aches, Across doses	3 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Muscle aches, Across doses	8 Participants	3 Participants	2 Participants	8 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Shivering, Across doses	5 Participants	2 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Shivering, Across doses	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Temperature (Axillary), Across doses	2 Participants	0 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Sweating, Across doses	4 Participants	2 Participants	3 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Sweating, Across doses	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Shivering, Dose 2	2 Participants	2 Participants	0 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Sweating, Dose 2	3 Participants	0 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Sweating, Dose 2	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Sweating, Dose 2	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Fatigue, Across doses	11 Participants	4 Participants	8 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Fatigue, Across doses	6 Participants	4 Participants	6 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Gastrointestinal symptoms, Across doses	3 Participants	3 Participants	4 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Headache, Across doses	12 Participants	4 Participants	5 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Headache, Across doses	6 Participants	3 Participants	4 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Joint pain at other location, Across doses	10 Participants	2 Participants	2 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Joint pain at other location, Across doses	2 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Muscle aches, Across doses	11 Participants	3 Participants	3 Participants	8 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Shivering, Across doses	2 Participants	2 Participants	0 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Sweating, Across doses	1 Participants	2 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Temperature (Axillary), Across doses	9 Participants	1 Participants	2 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Temperature (Axillary), Across doses	6 Participants	1 Participants	1 Participants	7 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Fatigue, Dose 1	1 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Gastrointestinal symptoms, Dose 2	2 Participants	1 Participants	4 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Headache, Dose 2	7 Participants	2 Participants	4 Participants	8 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Headache, Dose 2	1 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Headache, Dose 2	4 Participants	2 Participants	3 Participants	8 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Joint pain at other location, Dose 2	6 Participants	0 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Joint pain at other location, Dose 2	2 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Joint pain at other location, Dose 2	5 Participants	0 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Muscle aches, Dose 2	3 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Related Muscle aches, Dose 2	6 Participants	1 Participants	1 Participants	7 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Any Shivering, Dose 2	3 Participants	2 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis Grade 3 Shivering, Dose 2	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE), at Day 7 and at Day 21

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Among haematological parameters assessed were basophils [BAS], eosinophils [EOS], hematocrit [HCT], hemoglobin level [HGB], lymphocytes [LYM], monocytes [MON], neutrophils [NEU], platelet count [PLC], red blood cells [RBC] and white blood cells [WBC]. Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.

Outcome measures

Measure	Arepanrix/F2 Group n=60 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=60 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=61 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=66 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis RBC, PRE · Unknown	6 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis EOS, PRE · Above	2 Participants	2 Participants	4 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis EOS, D7 · Within	42 Participants	46 Participants	45 Participants	50 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis LYM, PRE · Above	8 Participants	6 Participants	6 Participants	8 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis PLC, D21 · Within	43 Participants	51 Participants	57 Participants	57 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis MON, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis RBC, D21 · Below	3 Participants	2 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis RBC, D21 · Within	51 Participants	48 Participants	57 Participants	62 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis WBC, PRE · Within	30 Participants	22 Participants	26 Participants	33 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis WBC, D7 · Below	2 Participants	1 Participants	1 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis WBC, D21 · Below	1 Participants	0 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis NEU, PRE · Above	2 Participants	3 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis NEU, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis NEU, D7 · Below	3 Participants	2 Participants	6 Participants	10 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis WBC, D21 · Above	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis BAS, PRE · Unknown	6 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis BAS, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis BAS, PRE · Within	31 Participants	24 Participants	28 Participants	35 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis BAS, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis BAS, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis BAS, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis BAS, D7 · Within	56 Participants	56 Participants	58 Participants	61 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis BAS, D7 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis BAS, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis BAS, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis BAS, D21 · Within	54 Participants	52 Participants	61 Participants	64 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis BAS, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis EOS, PRE · Unknown	6 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis EOS, PRE · Below	1 Participants	2 Participants	4 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis EOS, PRE · Within	28 Participants	20 Participants	20 Participants	28 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis EOS, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis EOS, D7 · Below	8 Participants	8 Participants	6 Participants	7 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis EOS, D7 · Above	6 Participants	2 Participants	7 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis EOS, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis EOS, D21 · Below	6 Participants	5 Participants	7 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis EOS, D21 · Within	42 Participants	46 Participants	51 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis EOS, D21 · Above	6 Participants	1 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HCT, PRE · Unknown	6 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HCT, PRE · Below	3 Participants	0 Participants	3 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HCT, PRE · Within	24 Participants	22 Participants	24 Participants	31 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HCT, PRE · Above	4 Participants	2 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HCT, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HCT, D7 · Below	7 Participants	4 Participants	6 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HCT, D7 · Within	47 Participants	48 Participants	49 Participants	52 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HCT, D7 · Above	2 Participants	4 Participants	3 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HCT, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HCT, D21 · Below	10 Participants	7 Participants	7 Participants	7 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HCT, D21 · Within	41 Participants	42 Participants	53 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HCT, D21 · Above	3 Participants	3 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HGB, PRE · Unknown	6 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HGB, PRE · Below	2 Participants	0 Participants	3 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HGB, PRE · Within	25 Participants	22 Participants	23 Participants	31 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HGB, PRE · Above	4 Participants	2 Participants	2 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HGB, D7 · Unknown	3 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HGB, D7 · Below	5 Participants	1 Participants	2 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HGB, D7 · Within	50 Participants	51 Participants	52 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HGB, D7 · Above	2 Participants	4 Participants	4 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HGB, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HGB, D21 · Below	3 Participants	3 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HGB, D21 · Within	48 Participants	46 Participants	56 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis HGB, D21 · Above	3 Participants	3 Participants	2 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis LYM, PRE · Unknown	6 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis LYM, PRE · Below	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis LYM, PRE · Within	23 Participants	17 Participants	22 Participants	27 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis LYM, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis LYM, D7 · Below	2 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis LYM, D7 · Within	28 Participants	33 Participants	44 Participants	38 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis LYM, D7 · Above	26 Participants	23 Participants	14 Participants	22 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis LYM, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis LYM, D21 · Below	1 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis LYM, D21 · Within	27 Participants	35 Participants	38 Participants	43 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis LYM, D21 · Above	26 Participants	17 Participants	22 Participants	21 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis MON, PRE · Unknown	6 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis MON, PRE · Below	5 Participants	3 Participants	5 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis MON, PRE · Within	26 Participants	21 Participants	22 Participants	31 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis MON, PRE · Above	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis MON, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis MON, D7 · Below	10 Participants	11 Participants	7 Participants	13 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis MON, D7 · Within	46 Participants	44 Participants	51 Participants	48 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis MON, D7 · Above	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis MON, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis MON, D21 · Below	8 Participants	10 Participants	13 Participants	19 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis MON, D21 · Within	46 Participants	42 Participants	48 Participants	45 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis NEU, PRE · Unknown	6 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis NEU, PRE · Below	2 Participants	0 Participants	3 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis NEU, PRE · Within	27 Participants	21 Participants	25 Participants	31 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis NEU, D7 · Within	52 Participants	54 Participants	50 Participants	50 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis NEU, D7 · Above	1 Participants	0 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis NEU, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis NEU, D21 · Below	3 Participants	3 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis NEU, D21 · Within	51 Participants	49 Participants	59 Participants	62 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis NEU, D21 · Above	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis PLC, PRE · Unknown	7 Participants	5 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis PLC, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis PLC, PRE · Within	26 Participants	20 Participants	27 Participants	33 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis PLC, PRE · Above	4 Participants	3 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis PLC, D7 · Unknown	3 Participants	4 Participants	3 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis PLC, D7 · Below	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis PLC, D7 · Within	49 Participants	50 Participants	51 Participants	51 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis PLC, D7 · Above	8 Participants	5 Participants	7 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis PLC, D21 · Unknown	4 Participants	6 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis PLC, D21 · Below	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis PLC, D21 · Above	9 Participants	1 Participants	4 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis RBC, PRE · Below	1 Participants	0 Participants	2 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis RBC, PRE · Within	29 Participants	23 Participants	25 Participants	34 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis RBC, PRE · Above	1 Participants	1 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis RBC, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis RBC, D7 · Below	3 Participants	1 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis RBC, D7 · Within	52 Participants	54 Participants	54 Participants	56 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis RBC, D7 · Above	1 Participants	1 Participants	3 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis RBC, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis RBC, D21 · Above	0 Participants	2 Participants	3 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis WBC, PRE · Unknown	6 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis WBC, PRE · Below	0 Participants	0 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis WBC, PRE · Above	1 Participants	2 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis WBC, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis WBC, D7 · Within	53 Participants	55 Participants	56 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis WBC, D7 · Above	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis WBC, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis WBC, D21 · Within	53 Participants	52 Participants	60 Participants	61 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE), at Day 7 and at Day 21

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Biochemical parameters assessed for lab abnormalities were alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin [BLR], bilirubin conjugated/direct [BCD], creatinine [CRE] and blood urea nitrogen [BUN]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.

Outcome measures

Measure	Arepanrix/F2 Group n=60 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=60 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=61 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=66 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BCD, PRE · Unkown	2 Participants	2 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis ALT, PRE · Within	35 Participants	27 Participants	28 Participants	37 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis AST, PRE · Unkown	5 Participants	3 Participants	0 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis AST, D7 · Unkown	3 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis AST, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BLR, D7 · Within	59 Participants	60 Participants	60 Participants	65 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BLR, D7 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BCD, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BCD, PRE · Within	35 Participants	27 Participants	28 Participants	37 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BCD, D7 · Within	59 Participants	60 Participants	60 Participants	65 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BCD, D21 · Unkown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis CRE, PRE · Unkown	2 Participants	2 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis CRE, D7 · Unkown	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis CRE, D7 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis CRE, D21 · Below	23 Participants	15 Participants	17 Participants	22 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BUN, PRE · Below	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BUN, PRE · Within	33 Participants	23 Participants	25 Participants	35 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BUN, PRE · Above	2 Participants	4 Participants	3 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BUN, D7 · Below	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BUN, D7 · Above	4 Participants	9 Participants	8 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BUN, D21 · Within	54 Participants	48 Participants	52 Participants	59 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BUN, D21 · Above	3 Participants	6 Participants	9 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BLR, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BLR, D21 · Within	57 Participants	54 Participants	61 Participants	63 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BLR, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis ALT, PRE · Unkown	2 Participants	2 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis ALT, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis ALT, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis ALT, D7 · Unkown	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis ALT, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis ALT, D7 · Within	59 Participants	59 Participants	59 Participants	64 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis ALT, D7 · Above	0 Participants	1 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis ALT, D21 · Unkown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis ALT, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis ALT, D21 · Within	57 Participants	54 Participants	61 Participants	63 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis ALT, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis AST, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis AST, PRE · Within	32 Participants	26 Participants	28 Participants	34 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis AST, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis AST, D7 · Within	57 Participants	57 Participants	58 Participants	63 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis AST, D7 · Above	0 Participants	3 Participants	2 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis AST, D21 · Unkown	0 Participants	4 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis AST, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis AST, D21 · Within	56 Participants	52 Participants	60 Participants	61 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis AST, D21 · Above	1 Participants	2 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BLR, PRE · Unkown	2 Participants	2 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BLR, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BLR, PRE · Within	35 Participants	27 Participants	28 Participants	37 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BLR, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BLR, D7 · Unkown	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BLR, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BLR, D21 · Unkown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BCD, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BCD, D7 · Unkown	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BCD, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BCD, D7 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BCD, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BCD, D21 · Within	57 Participants	54 Participants	61 Participants	63 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BCD, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis CRE, PRE · Below	15 Participants	10 Participants	7 Participants	13 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis CRE, PRE · Within	20 Participants	17 Participants	21 Participants	24 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis CRE, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis CRE, D7 · Below	23 Participants	19 Participants	17 Participants	18 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis CRE, D7 · Within	36 Participants	41 Participants	43 Participants	47 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis CRE, D21 · Unkown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis CRE, D21 · Within	34 Participants	39 Participants	44 Participants	41 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis CRE, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BUN, PRE · Unkown	2 Participants	2 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BUN, D7 · Unkown	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BUN, D7 · Within	55 Participants	51 Participants	51 Participants	62 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BUN, D21 · Unkown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis BUN, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE), at Day 7, at Day 21 and at Day 42

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Among haematological parameters assessed were basophils [BAS], eosinophils [EOS], hematocrit [HCT], hemoglobin level [HGB], lymphocytes [LYM], monocytes [MON], neutrophils [NEU], platelet count [PLC], red blood cells [RBC] and white blood cells [WBC]. Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.

Outcome measures

Measure	Arepanrix/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=66 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, PRE · Below	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, PRE · Within	49 Participants	48 Participants	56 Participants	51 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, PRE · Unknown	3 Participants	7 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, D42 · Within	46 Participants	50 Participants	47 Participants	42 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, D7 · Within	47 Participants	48 Participants	49 Participants	52 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, D7 · Above	2 Participants	4 Participants	3 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, PRE · Above	6 Participants	5 Participants	4 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, PRE · Within	60 Participants	56 Participants	61 Participants	65 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, D7 · Within	56 Participants	56 Participants	58 Participants	61 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, D7 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, D42 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, PRE · Unknown	2 Participants	6 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, PRE · Above	3 Participants	5 Participants	5 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, D7 · Within	42 Participants	46 Participants	45 Participants	50 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, PRE · Unknown	6 Participants	4 Participants	2 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, D7 · Unknown	3 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, D7 · Below	5 Participants	1 Participants	2 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, D7 · Within	50 Participants	51 Participants	52 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, D21 · Below	3 Participants	3 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, D21 · Within	48 Participants	47 Participants	56 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, D21 · Above	3 Participants	3 Participants	2 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, D42 · Unknown	2 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, D42 · Above	3 Participants	6 Participants	3 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, PRE · Unknown	4 Participants	6 Participants	2 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, PRE · Below	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, D21 · Within	27 Participants	36 Participants	38 Participants	43 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, D42 · Above	22 Participants	23 Participants	17 Participants	18 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, PRE · Unknown	5 Participants	6 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, PRE · Below	10 Participants	4 Participants	15 Participants	10 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, PRE · Within	48 Participants	53 Participants	46 Participants	52 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, D7 · Below	10 Participants	11 Participants	7 Participants	13 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, D7 · Within	46 Participants	44 Participants	51 Participants	48 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, D42 · Above	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, PRE · Above	1 Participants	2 Participants	3 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, D21 · Within	51 Participants	49 Participants	57 Participants	62 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, D21 · Above	0 Participants	2 Participants	3 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, D7 · Below	2 Participants	1 Participants	1 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, D42 · Unknown	2 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, D21 · Within	46 Participants	43 Participants	48 Participants	45 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, D42 · Unknown	2 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, D42 · Below	17 Participants	21 Participants	16 Participants	13 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, PRE · Unknown	8 Participants	8 Participants	3 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, D42 · Within	37 Participants	38 Participants	41 Participants	41 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, PRE · Unknown	4 Participants	4 Participants	1 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, PRE · Below	6 Participants	4 Participants	6 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, PRE · Within	52 Participants	51 Participants	56 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, PRE · Above	1 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, D7 · Below	3 Participants	2 Participants	6 Participants	10 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, D7 · Within	52 Participants	54 Participants	50 Participants	50 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, D7 · Above	1 Participants	0 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, D21 · Below	3 Participants	3 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, D21 · Within	51 Participants	50 Participants	59 Participants	62 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, D21 · Above	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, D42 · Unknown	2 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, D42 · Below	5 Participants	10 Participants	13 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, D42 · Within	48 Participants	48 Participants	40 Participants	50 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis NEU, D42 · Above	1 Participants	1 Participants	4 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, PRE · Above	6 Participants	6 Participants	4 Participants	11 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, D7 · Unknown	3 Participants	4 Participants	3 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, D7 · Below	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, D7 · Within	49 Participants	50 Participants	51 Participants	51 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, D7 · Above	8 Participants	5 Participants	7 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, D21 · Unknown	4 Participants	6 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, D21 · Below	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, D21 · Within	43 Participants	52 Participants	57 Participants	57 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, D21 · Above	9 Participants	1 Participants	4 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, D42 · Unknown	3 Participants	1 Participants	2 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, D42 · Below	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, D42 · Within	47 Participants	59 Participants	53 Participants	50 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis PLC, D42 · Above	6 Participants	0 Participants	2 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, PRE · Unknown	4 Participants	5 Participants	2 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, PRE · Below	4 Participants	0 Participants	3 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, PRE · Within	54 Participants	56 Participants	55 Participants	59 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, D7 · Below	3 Participants	1 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, D7 · Within	52 Participants	54 Participants	54 Participants	56 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, D7 · Above	1 Participants	1 Participants	3 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, D21 · Below	3 Participants	2 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, D42 · Unknown	2 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, D42 · Below	2 Participants	2 Participants	3 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, D42 · Within	52 Participants	55 Participants	52 Participants	51 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis RBC, D42 · Above	0 Participants	2 Participants	2 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, PRE · Unknown	5 Participants	6 Participants	2 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, PRE · Below	0 Participants	1 Participants	2 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, PRE · Within	57 Participants	54 Participants	59 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, PRE · Above	1 Participants	2 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, D7 · Within	53 Participants	55 Participants	56 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, D7 · Above	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, D21 · Below	1 Participants	0 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, D21 · Within	53 Participants	53 Participants	60 Participants	61 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, D21 · Above	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, D42 · Below	3 Participants	2 Participants	5 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, D42 · Within	51 Participants	56 Participants	50 Participants	52 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis WBC, D42 · Above	0 Participants	1 Participants	2 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, D21 · Within	54 Participants	53 Participants	61 Participants	64 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, D42 · Unknown	2 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, D42 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis BAS, D42 · Within	54 Participants	59 Participants	57 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, PRE · Below	5 Participants	7 Participants	6 Participants	12 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, PRE · Within	53 Participants	45 Participants	51 Participants	46 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, D7 · Below	8 Participants	8 Participants	6 Participants	7 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, D7 · Above	6 Participants	2 Participants	7 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, D21 · Below	6 Participants	5 Participants	7 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, D21 · Within	42 Participants	47 Participants	51 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, D21 · Above	6 Participants	1 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, D42 · Unknown	2 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, D42 · Below	3 Participants	5 Participants	3 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis EOS, D42 · Above	5 Participants	4 Participants	7 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, PRE · Unknown	5 Participants	6 Participants	2 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, PRE · Below	8 Participants	4 Participants	5 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, D7 · Below	2 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, PRE · Within	44 Participants	48 Participants	52 Participants	53 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, D7 · Below	7 Participants	4 Participants	6 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, D21 · Below	10 Participants	7 Participants	7 Participants	7 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, D21 · Within	41 Participants	43 Participants	53 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, D21 · Above	3 Participants	3 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, D42 · Unknown	2 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, D42 · Below	12 Participants	5 Participants	10 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, D42 · Within	41 Participants	48 Participants	46 Participants	45 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HCT, D42 · Above	1 Participants	6 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, PRE · Below	5 Participants	3 Participants	3 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, PRE · Within	45 Participants	52 Participants	55 Participants	58 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, PRE · Above	7 Participants	4 Participants	3 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, D7 · Above	2 Participants	4 Participants	4 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, D42 · Below	8 Participants	4 Participants	4 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis HGB, D42 · Within	43 Participants	49 Participants	50 Participants	49 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, PRE · Within	38 Participants	35 Participants	43 Participants	46 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, PRE · Above	21 Participants	21 Participants	18 Participants	18 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, D7 · Within	28 Participants	33 Participants	44 Participants	38 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, D7 · Above	26 Participants	23 Participants	14 Participants	22 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, D21 · Below	1 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, D21 · Above	26 Participants	17 Participants	22 Participants	21 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, D42 · Unknown	2 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, D42 · Below	1 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis LYM, D42 · Within	31 Participants	36 Participants	40 Participants	36 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, PRE · Above	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, D7 · Above	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, D21 · Unknown	3 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - First Analysis MON, D21 · Below	8 Participants	10 Participants	13 Participants	19 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE), at Day 7, at Day 21 and at Day 42

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Biochemical parameters assessed for lab abnormalities were alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin [BLR], bilirubin conjugated/direct [BCD], creatinine [CRE] and blood urea nitrogen [BUN]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.

Outcome measures

Measure	Arepanrix/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=66 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, D7 · Unknown	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, PRE · Within	57 Participants	59 Participants	63 Participants	61 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, D7 · Unknown	3 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, D7 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, D42 · Above	5 Participants	6 Participants	7 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, D21 · Within	57 Participants	55 Participants	61 Participants	63 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, D42 · Unknown	2 Participants	0 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, PRE · Unknown	2 Participants	3 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, PRE · Within	61 Participants	59 Participants	63 Participants	64 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, PRE · Above	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, D7 · Within	59 Participants	59 Participants	59 Participants	64 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, D7 · Above	0 Participants	1 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, D21 · Unknown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, D21 · Within	57 Participants	55 Participants	61 Participants	63 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, D42 · Unknown	2 Participants	0 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, D42 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, D42 · Within	53 Participants	59 Participants	56 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis ALT, D42 · Above	1 Participants	1 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, PRE · Unknown	6 Participants	3 Participants	0 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, PRE · Above	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, D7 · Within	57 Participants	57 Participants	58 Participants	63 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, D7 · Above	0 Participants	3 Participants	2 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, D21 · Unknown	0 Participants	4 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, D21 · Within	56 Participants	53 Participants	60 Participants	61 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, D21 · Above	1 Participants	2 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, D42 · Unknown	2 Participants	0 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, D42 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, D42 · Within	53 Participants	57 Participants	57 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis AST, D42 · Above	1 Participants	3 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, PRE · Unknown	1 Participants	3 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, PRE · Within	62 Participants	60 Participants	63 Participants	64 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, D7 · Unknown	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, D7 · Within	59 Participants	60 Participants	60 Participants	65 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, D21 · Unknown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, D42 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, D42 · Within	53 Participants	60 Participants	57 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BLR, D42 · Above	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, PRE · Unknown	2 Participants	3 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, PRE · Within	61 Participants	60 Participants	63 Participants	64 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, D7 · Unknown	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, D7 · Within	59 Participants	60 Participants	60 Participants	65 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, D7 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, D21 · Unknown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, D21 · Within	57 Participants	55 Participants	61 Participants	63 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, D42 · Unknown	2 Participants	0 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, D42 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, D42 · Within	54 Participants	60 Participants	57 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BCD, D42 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, PRE · Unknown	2 Participants	3 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, PRE · Below	22 Participants	17 Participants	15 Participants	19 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, PRE · Within	39 Participants	43 Participants	48 Participants	45 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, D7 · Unknown	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, D7 · Below	23 Participants	19 Participants	17 Participants	18 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, D7 · Within	36 Participants	41 Participants	43 Participants	47 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, D7 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, D21 · Unknown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, D21 · Below	23 Participants	15 Participants	17 Participants	22 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, D21 · Within	34 Participants	40 Participants	44 Participants	41 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, D42 · Unknown	2 Participants	0 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, D42 · Below	20 Participants	16 Participants	13 Participants	18 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, D42 · Within	34 Participants	44 Participants	44 Participants	37 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis CRE, D42 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, PRE · Unknown	2 Participants	3 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, PRE · Below	0 Participants	0 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, PRE · Within	55 Participants	55 Participants	58 Participants	58 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, PRE · Above	6 Participants	5 Participants	5 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, D7 · Unknown	1 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, D7 · Below	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, D7 · Within	55 Participants	51 Participants	51 Participants	62 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, D7 · Above	4 Participants	9 Participants	8 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, D21 · Unknown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, D21 · Within	54 Participants	49 Participants	52 Participants	59 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, D21 · Above	3 Participants	6 Participants	9 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, D42 · Unknown	2 Participants	0 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, D42 · Below	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis BUN, D42 · Within	49 Participants	54 Participants	50 Participants	49 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE), at Day 7 and at Day 21

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Among haematological parameters assessed were basophils [BAS], eosinophils [EOS], hematocrit [HCT], hemoglobin level [HGB], lymphocytes [LYM], monocytes [MON], neutrophils [NEU], platelet count [PLC], red blood cells [RBC] and white blood cells [WBC], Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.

Outcome measures

Measure	Arepanrix/F2 Group n=126 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=66 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, D7 · Within	98 Participants	51 Participants	52 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, D7 · Above	9 Participants	4 Participants	4 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, D21 · Unknown	4 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, D21 · Below	10 Participants	3 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, D21 · Within	97 Participants	47 Participants	56 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, D21 · Above	5 Participants	3 Participants	2 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, D42 · Unknown	5 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, D42 · Below	13 Participants	4 Participants	4 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, D42 · Within	90 Participants	49 Participants	50 Participants	49 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, D42 · Above	6 Participants	6 Participants	3 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, PRE · Unknown	5 Participants	3 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, PRE · Below	1 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, PRE · Within	121 Participants	60 Participants	62 Participants	65 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, D21 · Below	4 Participants	0 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, D7 · Below	9 Participants	1 Participants	2 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, PRE · Unknown	5 Participants	3 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, D7 · Unknown	5 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, D7 · Within	115 Participants	56 Participants	58 Participants	61 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, D7 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, D21 · Unknown	4 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, D21 · Within	112 Participants	53 Participants	61 Participants	64 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, D42 · Unknown	5 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, D42 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, D42 · Within	109 Participants	59 Participants	57 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis BAS, D42 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, PRE · Unknown	5 Participants	3 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, PRE · Below	11 Participants	7 Participants	6 Participants	12 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, PRE · Within	100 Participants	48 Participants	51 Participants	49 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, PRE · Above	10 Participants	5 Participants	5 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, D7 · Unknown	5 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, D7 · Below	20 Participants	8 Participants	6 Participants	7 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, D7 · Within	84 Participants	46 Participants	45 Participants	50 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, D7 · Above	11 Participants	2 Participants	7 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, D21 · Unknown	4 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, D21 · Below	14 Participants	5 Participants	7 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, D21 · Within	90 Participants	47 Participants	51 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, D21 · Above	8 Participants	1 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, D42 · Unknown	5 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, D42 · Below	8 Participants	5 Participants	3 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, D42 · Within	94 Participants	50 Participants	47 Participants	42 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis EOS, D42 · Above	7 Participants	4 Participants	7 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, PRE · Unknown	6 Participants	3 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, PRE · Below	22 Participants	5 Participants	6 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, PRE · Within	90 Participants	50 Participants	52 Participants	56 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, PRE · Above	8 Participants	5 Participants	4 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, D7 · Unknown	5 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, D7 · Below	26 Participants	4 Participants	6 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, D7 · Within	82 Participants	48 Participants	49 Participants	52 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, D7 · Above	7 Participants	4 Participants	3 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, D21 · Unknown	4 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, D21 · Below	32 Participants	7 Participants	7 Participants	7 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, D21 · Within	77 Participants	43 Participants	53 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, D21 · Above	3 Participants	3 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, D42 · Unknown	6 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, D42 · Below	24 Participants	5 Participants	10 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, D42 · Within	80 Participants	48 Participants	46 Participants	45 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HCT, D42 · Above	4 Participants	6 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, PRE · Unknown	5 Participants	3 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, PRE · Below	15 Participants	3 Participants	4 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, PRE · Within	96 Participants	53 Participants	55 Participants	59 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, PRE · Above	10 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis HGB, D7 · Unknown	4 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, PRE · Within	83 Participants	37 Participants	44 Participants	47 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, PRE · Above	37 Participants	22 Participants	18 Participants	18 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, D7 · Unknown	5 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, D7 · Below	3 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, D7 · Within	73 Participants	33 Participants	44 Participants	38 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, D7 · Above	39 Participants	23 Participants	14 Participants	22 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, D21 · Unknown	4 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, D21 · Below	2 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, D21 · Within	72 Participants	36 Participants	38 Participants	43 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, D21 · Above	38 Participants	17 Participants	22 Participants	21 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, D42 · Unknown	5 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, D42 · Below	3 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, D42 · Within	75 Participants	36 Participants	40 Participants	36 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis LYM, D42 · Above	31 Participants	23 Participants	17 Participants	18 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, PRE · Unknown	5 Participants	3 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, PRE · Below	26 Participants	7 Participants	15 Participants	12 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, PRE · Within	95 Participants	53 Participants	46 Participants	53 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, PRE · Above	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, D7 · Unknown	5 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, D7 · Below	19 Participants	11 Participants	7 Participants	13 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, D7 · Within	96 Participants	44 Participants	51 Participants	48 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, D7 · Above	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, D21 · Unknown	4 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, D21 · Below	18 Participants	10 Participants	13 Participants	19 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, D21 · Within	94 Participants	43 Participants	48 Participants	45 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, D42 · Unknown	5 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, D42 · Below	22 Participants	21 Participants	16 Participants	13 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, D42 · Within	87 Participants	38 Participants	41 Participants	41 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis MON, D42 · Above	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, PRE · Unknown	5 Participants	3 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, PRE · Below	9 Participants	4 Participants	6 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, PRE · Within	109 Participants	52 Participants	56 Participants	57 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, PRE · Above	3 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, D7 · Unknown	5 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, D7 · Below	4 Participants	2 Participants	6 Participants	10 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, D7 · Within	109 Participants	54 Participants	50 Participants	50 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, D7 · Above	2 Participants	0 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, D21 · Unknown	4 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, D21 · Below	10 Participants	3 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, D21 · Within	100 Participants	50 Participants	59 Participants	62 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, D21 · Above	2 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, D42 · Unknown	5 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, D42 · Below	12 Participants	10 Participants	13 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, D42 · Within	96 Participants	48 Participants	40 Participants	50 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis NEU, D42 · Above	1 Participants	1 Participants	4 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, PRE · Unknown	6 Participants	5 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, PRE · Below	1 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, PRE · Within	107 Participants	51 Participants	57 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, PRE · Above	12 Participants	6 Participants	4 Participants	11 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, D7 · Unknown	5 Participants	4 Participants	3 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, D7 · Below	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, D7 · Within	95 Participants	50 Participants	51 Participants	51 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, D7 · Above	20 Participants	5 Participants	7 Participants	9 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, D21 · Unknown	7 Participants	6 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, D21 · Below	2 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, D21 · Within	89 Participants	52 Participants	57 Participants	57 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, D21 · Above	18 Participants	1 Participants	4 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, D42 · Unknown	6 Participants	1 Participants	2 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, D42 · Below	0 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, D42 · Within	93 Participants	59 Participants	53 Participants	50 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis PLC, D42 · Above	15 Participants	0 Participants	2 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, PRE · Unknown	6 Participants	3 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, PRE · Below	6 Participants	0 Participants	3 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, PRE · Within	113 Participants	58 Participants	56 Participants	62 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, PRE · Above	1 Participants	2 Participants	3 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, D7 · Unknown	5 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, D7 · Below	4 Participants	1 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, D7 · Within	110 Participants	54 Participants	54 Participants	56 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, D7 · Above	1 Participants	1 Participants	3 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, D21 · Unknown	4 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, D21 · Below	5 Participants	2 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, D21 · Within	107 Participants	49 Participants	57 Participants	62 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, D21 · Above	0 Participants	2 Participants	3 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, D42 · Unknown	6 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, D42 · Below	4 Participants	2 Participants	3 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, D42 · Within	103 Participants	55 Participants	52 Participants	51 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis RBC, D42 · Above	1 Participants	2 Participants	2 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, PRE · Unknown	5 Participants	3 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, PRE · Below	0 Participants	1 Participants	2 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, PRE · Within	118 Participants	57 Participants	60 Participants	59 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, PRE · Above	3 Participants	2 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, D7 · Unknown	5 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, D7 · Below	3 Participants	1 Participants	1 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, D7 · Within	110 Participants	55 Participants	56 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, D7 · Above	2 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, D21 · Unknown	4 Participants	6 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, D21 · Within	107 Participants	53 Participants	60 Participants	61 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, D21 · Above	1 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, D42 · Unknown	5 Participants	1 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, D42 · Below	7 Participants	2 Participants	5 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, D42 · Within	102 Participants	56 Participants	50 Participants	52 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis WBC, D42 · Above	0 Participants	1 Participants	2 Participants	0 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0 (PRE), at Day 7, at Day 21 and at Day 42

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Biochemical parameters assessed for lab abnormalities were alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin [BLR], bilirubin conjugated/direct [BCD], creatinine [CRE] and blood urea nitrogen [BUN]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.

Outcome measures

Measure	Arepanrix/F2 Group n=126 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=66 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, PRE · Above	5 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, D7 · Unknown	4 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, D7 · Unknown	2 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, PRE · Unknown	2 Participants	3 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, PRE · Within	124 Participants	59 Participants	63 Participants	64 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, PRE · Above	0 Participants	1 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, D7 · Unknown	2 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, D7 · Within	118 Participants	59 Participants	59 Participants	64 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, D7 · Above	0 Participants	1 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, D21 · Unknown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, D21 · Within	115 Participants	55 Participants	61 Participants	63 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, D21 · Above	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, D42 · Unknown	3 Participants	0 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, D42 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, D42 · Within	110 Participants	59 Participants	56 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis ALT, D42 · Above	1 Participants	1 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, PRE · Unknown	4 Participants	3 Participants	0 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, PRE · Within	117 Participants	59 Participants	63 Participants	62 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, D7 · Within	113 Participants	57 Participants	58 Participants	63 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, D7 · Above	3 Participants	3 Participants	2 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, D21 · Unknown	1 Participants	4 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, D21 · Within	112 Participants	53 Participants	60 Participants	61 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, D21 · Above	3 Participants	2 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, D42 · Unknown	3 Participants	0 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, D42 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, D42 · Within	105 Participants	57 Participants	57 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis AST, D42 · Above	6 Participants	3 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, PRE · Unknown	2 Participants	3 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, PRE · Within	124 Participants	60 Participants	63 Participants	64 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, D7 · Below	1 Participants	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, D7 · Unknown	2 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, D7 · Within	118 Participants	60 Participants	60 Participants	65 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, D7 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, D21 · Unknown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, D21 · Within	116 Participants	55 Participants	61 Participants	63 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, D42 · Unknown	3 Participants	0 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, D42 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, D42 · Within	110 Participants	60 Participants	57 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, D7 · Within	110 Participants	51 Participants	51 Participants	62 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BLR, D42 · Above	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, PRE · Unknown	2 Participants	3 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, PRE · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, PRE · Within	124 Participants	60 Participants	63 Participants	64 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, PRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, D7 · Unknown	2 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, D7 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, D7 · Within	118 Participants	60 Participants	60 Participants	65 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, D7 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, D21 · Unknown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, D21 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, D21 · Within	116 Participants	55 Participants	61 Participants	63 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, D42 · Unknown	3 Participants	0 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, D42 · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, D42 · Within	111 Participants	60 Participants	57 Participants	55 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BCD, D42 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, PRE · Unknown	2 Participants	3 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, PRE · Below	38 Participants	17 Participants	15 Participants	19 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, PRE · Within	86 Participants	43 Participants	48 Participants	45 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, D7 · Unknown	2 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, D7 · Below	38 Participants	19 Participants	17 Participants	18 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, D7 · Within	80 Participants	41 Participants	43 Participants	47 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, D7 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, D21 · Unknown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, D21 · Below	40 Participants	15 Participants	17 Participants	22 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, D21 · Within	76 Participants	40 Participants	44 Participants	41 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, D21 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, D42 · Unknown	3 Participants	0 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, D42 · Below	37 Participants	16 Participants	13 Participants	18 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, D42 · Within	74 Participants	44 Participants	44 Participants	37 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis CRE, D42 · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, PRE · Unknown	2 Participants	3 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, PRE · Below	4 Participants	0 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, PRE · Within	110 Participants	56 Participants	58 Participants	58 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, PRE · Above	10 Participants	4 Participants	5 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, D7 · Above	7 Participants	9 Participants	8 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, D21 · Unknown	0 Participants	4 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, D21 · Below	4 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, D21 · Within	107 Participants	49 Participants	52 Participants	59 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, D21 · Above	5 Participants	6 Participants	9 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, D42 · Unknown	3 Participants	0 Participants	1 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, D42 · Below	4 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, D42 · Within	96 Participants	54 Participants	50 Participants	49 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis BUN, D42 · Above	11 Participants	6 Participants	7 Participants	5 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 182

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Among haematological parameters assessed were basophils [BAS], eosinophils [EOS], hematocrit [HCT], hemoglobin level [HGB], lymphocytes [LYM], monocytes [MON], neutrophils [NEU], platelet count [PLC], red blood cells [RBC] and white blood cells [WBC]. Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.

Outcome measures

Measure	Arepanrix/F2 Group n=108 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=53 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=56 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=59 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Haematological Laboratory Abnormalities BAS · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities MON · Within	82 Participants	39 Participants	40 Participants	35 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities RBC · Above	2 Participants	0 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities WBC · Unknown	8 Participants	2 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities BAS · Unknown	8 Participants	2 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities BAS · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities BAS · Within	100 Participants	51 Participants	53 Participants	54 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities EOS · Unknown	8 Participants	2 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities EOS · Below	10 Participants	8 Participants	3 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities EOS · Within	83 Participants	39 Participants	47 Participants	43 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities EOS · Above	7 Participants	4 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities HCT · Unknown	9 Participants	3 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities HCT · Below	17 Participants	5 Participants	7 Participants	8 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities HCT · Within	70 Participants	42 Participants	43 Participants	43 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities HCT · Above	12 Participants	3 Participants	3 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities HGB · Unknown	8 Participants	2 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities HGB · Below	8 Participants	3 Participants	4 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities HGB · Within	79 Participants	44 Participants	45 Participants	50 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities HGB · Above	13 Participants	4 Participants	4 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities LYM · Unknown	8 Participants	2 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities LYM · Below	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities LYM · Within	72 Participants	37 Participants	41 Participants	40 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities LYM · Above	28 Participants	14 Participants	12 Participants	13 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities MON · Unknown	8 Participants	2 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities MON · Below	18 Participants	12 Participants	13 Participants	18 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities MON · Above	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities NEU · Unknown	8 Participants	2 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities NEU · Below	8 Participants	5 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities NEU · Within	92 Participants	43 Participants	51 Participants	48 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities NEU · Above	0 Participants	3 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities PLC · Unknown	9 Participants	2 Participants	3 Participants	6 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities PLC · Below	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities PLC · Within	92 Participants	51 Participants	52 Participants	48 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities PLC · Above	6 Participants	0 Participants	1 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities RBC · Unknown	9 Participants	3 Participants	3 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities RBC · Below	6 Participants	3 Participants	1 Participants	2 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities RBC · Within	91 Participants	47 Participants	51 Participants	51 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities WBC · Below	2 Participants	2 Participants	1 Participants	5 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities WBC · Within	98 Participants	47 Participants	51 Participants	49 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Haematological Laboratory Abnormalities WBC · Above	0 Participants	2 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: At Day 182

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Biochemical parameters assessed for lab abnormalities were alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin [BLR], bilirubin conjugated/direct [BCD], creatinine [CRE] and blood urea nitrogen [BUN]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.

Outcome measures

Measure	Arepanrix/F2 Group n=108 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=53 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=56 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=59 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Biochemical Laboratory Abnormalities AST · Within	106 Participants	50 Participants	53 Participants	57 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities ALT · Unknown	1 Participants	1 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities ALT · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities ALT · Within	107 Participants	51 Participants	54 Participants	58 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities ALT · Above	0 Participants	1 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities AST · Unknown	1 Participants	1 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities AST · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities AST · Above	1 Participants	2 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities BLR · Unknown	1 Participants	1 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities BLR · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities BLR · Within	107 Participants	52 Participants	55 Participants	58 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities BLR · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities BCD · Unknown	1 Participants	1 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities BCD · Below	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities BCD · Within	106 Participants	52 Participants	55 Participants	58 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities BCD · Above	1 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities CRE · Unknown	1 Participants	1 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities CRE · Below	35 Participants	16 Participants	18 Participants	18 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities CRE · Within	72 Participants	36 Participants	37 Participants	40 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities CRE · Above	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities BUN · Unknown	1 Participants	1 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities BUN · Below	2 Participants	1 Participants	0 Participants	3 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities BUN · Within	99 Participants	48 Participants	53 Participants	51 Participants	—	—	—	—	—	—	—	—	—
Number of Subjects With Biochemical Laboratory Abnormalities BUN · Above	6 Participants	3 Participants	2 Participants	4 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 21 days (Days 0-20) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Any Unsolicited Adverse Events (AEs) - Preliminary Analysis	20 Participants	16 Participants	14 Participants	17 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 42 days (Days 0-41) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Any Unsolicited Adverse Events (AEs) - First Analysis	35 Participants	25 Participants	23 Participants	33 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 41 days (Days 0-40) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=128 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Any Unsolicited Adverse Events (AEs) - Second Analysis	65 Participants	24 Participants	23 Participants	34 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 84 days (Days 0-83) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=128 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Any Unsolicited Adverse Events (AEs)	76 Participants	30 Participants	32 Participants	36 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 21 days (Days 0-20) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Preliminary Analysis	5 Participants	3 Participants	4 Participants	7 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 41 days (Days 0-40) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Any Medically-attended Adverse Events (MAEs) - First Analysis	14 Participants	8 Participants	9 Participants	18 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 42 days (Days 0-41) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=128 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Second Analysis	31 Participants	8 Participants	9 Participants	18 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 182 days (Days 0-181) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=128 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Any Medically-attended Adverse Events (MAEs)	62 Participants	24 Participants	25 Participants	32 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Throughout the entire study period (Day 0 - Day 385)

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.

Outcome measures

Measure	Arepanrix/F2 Group n=128 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Any Medically-attended Adverse Events (MAEs)	87 Participants	39 Participants	34 Participants	39 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 21 days (Days 0-20) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Outcome measures

Measure	Arepanrix/F2 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Preliminary Analysis	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 42 days (Days 0-41) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Outcome measures

Measure	Arepanrix/F2 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - First Analysis	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 42 days (Days 0-41) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Outcome measures

Measure	Arepanrix/F2 Group n=128 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Second Analysis	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 182 days (Days 0-181) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Outcome measures

Measure	Arepanrix/F2 Group n=128 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Throughout the entire study period (Day 0 - Day 385)

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Outcome measures

Measure	Arepanrix/F2 Group n=128 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 21 days (Days 0-20) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Outcome measures

Measure	Arepanrix/F2 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Serious Adverse Events (SAEs) - Preliminary Analysis	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 42 days (Days 0-41) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Outcome measures

Measure	Arepanrix/F2 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Serious Adverse Events (SAEs) - First Analysis	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 42 days (Day 0-41) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Outcome measures

Measure	Arepanrix/F2 Group n=128 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Serious Adverse Events (SAEs) - Second Analysis	0 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Within 182 days (Days 0-181) post vaccination

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Outcome measures

Measure	Arepanrix/F2 Group n=128 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Serious Adverse Events (SAEs)	2 Participants	0 Participants	0 Participants	1 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Throughout the entire study period (Day 0 - Day 385)

Population: The analysis was performed on the Total Vaccinated Cohort, which included all subjects who received at least 1 study vaccination.

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Outcome measures

Measure	Arepanrix/F2 Group n=128 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F1 Group n=67 Participants Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-5Y Group Subjects, aged 6 months (M) - 5 years (Y), male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6M-35M Group Subjects, aged 6 months (M) - 35 months, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 3Y-6Y Group Subjects, aged 3 years (Y) - 6 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 6Y-9Y Group Subjects, aged 6 years (Y) - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Number of Subjects With Serious Adverse Events (SAEs)	2 Participants	0 Participants	0 Participants	2 Participants	—	—	—	—	—	—	—	—	—

Adverse Events

Arepanrix/F1 Group

Serious events: 2 serious events

Other events: 61 other events

Deaths: 0 deaths

Arepanrix/F2 Group

Serious events: 2 serious events

Other events: 125 other events

Deaths: 0 deaths

GSK2340273A/F1 Group

Serious events: 0 serious events

Other events: 54 other events

Deaths: 0 deaths

GSK2340273A/F2 Group

Serious events: 0 serious events

Other events: 55 other events

Deaths: 0 deaths

Serious adverse events

Measure	Arepanrix/F1 Group n=67 participants at risk Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F2 Group n=128 participants at risk Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 participants at risk Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 participants at risk Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
Infections and infestations Appendiceal abscess	0.00% 0/67 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	0.78% 1/128 • Number of events 2 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	0.00% 0/64 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	0.00% 0/63 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Infections and infestations Tonsillitis	1.5% 1/67 • Number of events 1 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	0.00% 0/128 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	0.00% 0/64 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	0.00% 0/63 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Nervous system disorders Convulsion	1.5% 1/67 • Number of events 1 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	0.78% 1/128 • Number of events 1 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	0.00% 0/64 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	0.00% 0/63 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).

Other adverse events

Measure	Arepanrix/F1 Group n=67 participants at risk Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	Arepanrix/F2 Group n=128 participants at risk Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F1 Group n=64 participants at risk Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).	GSK2340273A/F2 Group n=63 participants at risk Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children \< 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children \< 12 months of age).
General disorders Pain	76.1% 51/67 • Number of events 77 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	71.1% 91/128 • Number of events 148 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	53.1% 34/64 • Number of events 50 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	47.6% 30/63 • Number of events 41 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
General disorders Pyrexia	47.8% 32/67 • Number of events 36 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	32.0% 41/128 • Number of events 50 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	17.2% 11/64 • Number of events 12 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	15.9% 10/63 • Number of events 11 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Nervous system disorders Somnolence	25.4% 17/67 • Number of events 24 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	32.8% 42/128 • Number of events 51 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	20.3% 13/64 • Number of events 15 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	22.2% 14/63 • Number of events 16 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
General disorders Swelling	10.4% 7/67 • Number of events 9 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	11.7% 15/128 • Number of events 17 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	1.6% 1/64 • Number of events 1 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	1.6% 1/63 • Number of events 1 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Infections and infestations Upper respiratory tract infection	7.5% 5/67 • Number of events 6 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	9.4% 12/128 • Number of events 12 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	6.2% 4/64 • Number of events 4 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	3.2% 2/63 • Number of events 2 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Gastrointestinal disorders Vomiting	6.0% 4/67 • Number of events 4 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	4.7% 6/128 • Number of events 6 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	3.1% 2/64 • Number of events 2 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	9.5% 6/63 • Number of events 7 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Musculoskeletal and connective tissue disorders Arthralgia	3.0% 2/67 • Number of events 2 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	8.6% 11/128 • Number of events 12 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	3.1% 2/64 • Number of events 2 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	3.2% 2/63 • Number of events 2 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
General disorders Chills	6.0% 4/67 • Number of events 4 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	3.9% 5/128 • Number of events 5 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	3.1% 2/64 • Number of events 3 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	3.2% 2/63 • Number of events 2 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Respiratory, thoracic and mediastinal disorders Cough	4.5% 3/67 • Number of events 3 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	15.6% 20/128 • Number of events 23 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	9.4% 6/64 • Number of events 7 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	9.5% 6/63 • Number of events 6 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Metabolism and nutrition disorders Decreased appetite	40.3% 27/67 • Number of events 36 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	35.2% 45/128 • Number of events 54 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	18.8% 12/64 • Number of events 14 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	17.5% 11/63 • Number of events 14 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Skin and subcutaneous tissue disorders Erythema	20.9% 14/67 • Number of events 18 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	10.2% 13/128 • Number of events 14 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	1.6% 1/64 • Number of events 1 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	3.2% 2/63 • Number of events 2 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
General disorders Fatigue	9.0% 6/67 • Number of events 6 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	8.6% 11/128 • Number of events 15 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	6.2% 4/64 • Number of events 7 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	12.7% 8/63 • Number of events 8 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Gastrointestinal disorders Gastrointestinal disorder	1.5% 1/67 • Number of events 1 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	6.2% 8/128 • Number of events 10 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	4.7% 3/64 • Number of events 4 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	11.1% 7/63 • Number of events 7 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Nervous system disorders Headache	16.4% 11/67 • Number of events 15 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	11.7% 15/128 • Number of events 19 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	6.2% 4/64 • Number of events 4 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	9.5% 6/63 • Number of events 8 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Psychiatric disorders Irritability	41.8% 28/67 • Number of events 41 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	39.1% 50/128 • Number of events 69 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	32.8% 21/64 • Number of events 28 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	27.0% 17/63 • Number of events 19 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Musculoskeletal and connective tissue disorders Myalgia	11.9% 8/67 • Number of events 11 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	8.6% 11/128 • Number of events 15 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	4.7% 3/64 • Number of events 4 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	4.8% 3/63 • Number of events 3 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Infections and infestations Nasopharyngitis	6.0% 4/67 • Number of events 5 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	7.8% 10/128 • Number of events 11 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	6.2% 4/64 • Number of events 6 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	9.5% 6/63 • Number of events 8 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).
Infections and infestations Otitis media	3.0% 2/67 • Number of events 2 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	6.2% 8/128 • Number of events 10 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	3.1% 2/64 • Number of events 2 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).	4.8% 3/63 • Number of events 4 • Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6). Unsolicited AEs: during the 84-day post-vaccination (Days 0-83). SAEs: during the entire study period (Day 0 - Day 385).

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Results disclosure agreements

• Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
• Publication restrictions are in place

Restriction type: OTHER